These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9703296)

  • 1. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota.
    Chabolla DR; Maraganore DM; Ahlskog JE; O'Brien PC; Rocca WA
    Mayo Clin Proc; 1998 Aug; 73(8):724-7. PubMed ID: 9703296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
    Morley JF; Pawlowski SM; Kesari A; Maina I; Pantelyat A; Duda JE
    Parkinsonism Relat Disord; 2014 Jul; 20(7):738-42. PubMed ID: 24742370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Number of children and risk of Parkinson's disease.
    Frigerio R; Breteler MM; de Lau LM; Sanft KR; Bower JH; Ahlskog JE; Grossardt BR; ; Maraganore DM; Rocca WA
    Mov Disord; 2007 Apr; 22(5):632-9. PubMed ID: 17265462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study.
    Elbaz A; Peterson BJ; Bower JH; Yang P; Maraganore DM; McDonnell SK; Ahlskog JE; Rocca WA
    Mov Disord; 2005 Jun; 20(6):719-25. PubMed ID: 15704188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of coffee consumption and risk of Parkinson's disease.
    Sääksjärvi K; Knekt P; Rissanen H; Laaksonen MA; Reunanen A; Männistö S
    Eur J Clin Nutr; 2008 Jul; 62(7):908-15. PubMed ID: 17522612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of parkinsonism-Parkinson's disease in residents of adjacent kibbutzim in Israel's Negev.
    Goldsmith JR; Herishanu YO; Podgaietski M; Kordysh E
    Environ Res; 1997; 73(1-2):156-61. PubMed ID: 9311541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
    Huang HC; Tsai CH; Muo CH; Lin KH; Lu MK; Sung FC; Kao CH
    J Clin Psychiatry; 2015 Jan; 76(1):e104-10. PubMed ID: 25650675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study.
    McDonnell SK; Schaid DJ; Elbaz A; Strain KJ; Bower JH; Ahlskog JE; Maraganore DM; Rocca WA
    Ann Neurol; 2006 May; 59(5):788-95. PubMed ID: 16634030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial aggregation of Parkinson's disease: The Mayo Clinic family study.
    Rocca WA; McDonnell SK; Strain KJ; Bower JH; Ahlskog JE; Elbaz A; Schaid DJ; Maraganore DM
    Ann Neurol; 2004 Oct; 56(4):495-502. PubMed ID: 15455403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of parkinsonism: incidence, classification, and mortality.
    Rajput AH; Offord KP; Beard CM; Kurland LT
    Ann Neurol; 1984 Sep; 16(3):278-82. PubMed ID: 6333204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.
    Kitzmann AS; Pulido JS; Diehl NN; Hodge DO; Burke JP
    Ophthalmology; 2008 Jan; 115(1):169-73. PubMed ID: 18166410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia.
    Melton LJ; Leibson CL; Achenbach SJ; Bower JH; Maraganore DM; Oberg AL; Rocca WA
    Mov Disord; 2006 Sep; 21(9):1361-7. PubMed ID: 16703587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical exposures and Parkinson's disease: a population-based case-control study.
    Frigerio R; Sanft KR; Grossardt BR; Peterson BJ; Elbaz A; Bower JH; Ahlskog JE; de Andrade M; Maraganore DM; Rocca WA
    Mov Disord; 2006 Oct; 21(10):1688-92. PubMed ID: 16773614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
    Postuma RB; Lang AE; Gagnon JF; Pelletier A; Montplaisir JY
    Brain; 2012 Jun; 135(Pt 6):1860-70. PubMed ID: 22561644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Savica R; Grossardt BR; Bower JH; Ahlskog JE; Mielke MM; Rocca WA
    Mov Disord; 2017 Feb; 32(2):227-234. PubMed ID: 27779780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study.
    Dick FD; De Palma G; Ahmadi A; Scott NW; Prescott GJ; Bennett J; Semple S; Dick S; Counsell C; Mozzoni P; Haites N; Wettinger SB; Mutti A; Otelea M; Seaton A; Söderkvist P; Felice A;
    Occup Environ Med; 2007 Oct; 64(10):666-72. PubMed ID: 17332139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
    Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.